Silexion Therapeutics Q3 net loss narrows 24% year over year to $2.5 million
SLXN•Silexion Therapeutics’ third-quarter 2026 net loss narrowed 24% year over year to $2.53 million. Cash and cash equivalents were $4.76 million at September 30, while the first patient received SIL204 in its Phase 2/3 pancreatic cancer trial.
1. Quarterly results
Silexion Therapeutics reported a third-quarter 2026 net loss of $2.53 million, down 24% year over year. Research and development expenses fell 41% to $1.29 million.
2. Cash and trial update
The company had $4.76 million in cash and cash equivalents and shareholders’ equity of $2.97 million at September 30, 2026. The first patient received SIL204 in its Phase 2/3 pancreatic cancer trial, and additional sites in Israel and Germany are expected in coming months.
